BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-1451 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-1451\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07570147-11122@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:ABBV-1451: Phase 1 readout est. (NCT07570147)
DESCRIPTION:ABBV-1451\, phase 1.\nStudy: A Study to Evaluate the Pharmacoki
 netics\, Safety\, and Tolerability of Single Ascending Doses of ABBV-1451 
 Infusions and Injections in Healthy Adult Participants\nEstimated primary 
 completion: April 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/abbv-1451#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07570147
URL:https://assetmemo.bio/drug/abbv-1451#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
